Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe question of which weight loss injection ranks number one in the UK comes up constantly right now, and the short answer is that tirzepatide (Mounjaro) currently leads the clinical evidence: in the SURMOUNT-1 trial it produced an average body-weight reduction of around 20–21% over 72 weeks — greater than any other licensed injection in the UK. Semaglutide (Wegovy) is a closely contested second, with newer higher-dose options narrowing that gap. Both are prescription-only medicines that require a clinical assessment before a prescriber can approve them, so 'number one' only matters if the medicine is right for you as an individual. This page sets out what the trial data actually shows, how these injections work, who they are licensed for, and how to access them through a regulated route.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
When people search for the 'number one' weight loss injection, they are usually asking which one produces the most weight loss, and our page on the number one weight loss injection breaks down how that question is answered by the clinical evidence. The largest head-to-head evidence comes from the SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, which compared tirzepatide directly with semaglutide 2.4mg over 72 weeks in adults with obesity and without diabetes. Tirzepatide produced the greater average weight reduction. Before SURMOUNT-5, the comparison was indirect: SURMOUNT-1 (tirzepatide, ~2,500 participants) reported roughly 20–21% average loss at 15mg, while the STEP 1 trial (semaglutide 2.4mg) reported around 15%.
The picture shifted again when the MHRA approved the Wegovy 7.2mg single-dose pen in April 2026. Trials of that higher dose reported approximately 20.7% average loss over 72 weeks, which puts it in similar territory to tirzepatide. In practical terms, the gap between the two medicines is narrower now than it was two years ago. Our overview of weight loss injections sets out both medicines side by side with their licensed uses and eligibility thresholds. Which one is better for you is genuinely a clinical question, the answer depends on your health history, other medications, and how you tolerate each medicine.
One more thing worth knowing: trial averages mask a wide range of individual responses. Some participants lose considerably more than the average; others less. A single headline figure does not tell you what you personally will experience.
Both Mounjaro and Wegovy are licensed for adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes, prediabetes, or obstructive sleep apnoea. Lower BMI thresholds can apply for some ethnic backgrounds under UK clinical guidance. BMI alone is not the whole picture, a prescriber looks at your full health history, current medicines, and any contraindications before making a clinical decision.
A question our prescribers hear most weeks is whether someone with a BMI just under 30, and no listed comorbidity, can access either injection. For private prescribing, the licensed thresholds above apply. There is no shortcut around them, and any service offering these medicines without a proper clinical assessment is not operating within the law. You can read more about how eligibility works across different weight loss injections to see which conditions qualify and what the assessment process involves.
Pregnancy, breastfeeding, and planning to conceive are all situations where neither medicine is recommended. The same applies to anyone under 18. People with a history of medullary thyroid carcinoma, MEN2, or certain gastrointestinal conditions will need to discuss their suitability carefully with a prescriber. These are not bureaucratic hurdles; they are safety-critical checks.
Both medicines start at a low tolerability dose rather than the therapeutic dose seen in trials. Tirzepatide begins at 2.5mg; the first pen's job is to let your system adjust, reducing the likelihood of significant nausea during the weeks that follow. Dose increases are managed by your prescriber, typically in four-week steps, up to the highest dose you tolerate well. Wegovy follows a similar principle: the starting dose is 0.25mg, titrating up through several steps before reaching the maintenance dose.
The most common side effects during this process are gastrointestinal: nausea, changes in bowel habits, indigestion, and reduced appetite. These are generally most noticeable after starting or after a dose increase, and they tend to settle. If you are researching a weight loss injection r starting with that letter and want to understand how Rybelsus or related options compare on side effects and titration, our dedicated page covers the specifics. Injections are given once a week into the abdomen, thigh, or upper arm, rotating the site each time. If you are at the start of your research into how injections are administered day to day, this guide to Mounjaro injections covers the practical steps.
Safe disposal matters too. Every used pen is clinical waste. A sharps container keeps used pens safely contained until your local council or pharmacy sharps scheme collects them.
Mounjaro and Wegovy are prescription-only medicines. In the UK that means the only lawful route to either is a prescription issued by a registered prescriber following a genuine clinical assessment. On the NHS, both medicines are available but access is phased and the waiting lists for Wegovy through specialist services can be long. Mounjaro is rolling out through GP practices from 2025 onwards, but criteria are strict and availability varies by area.
Private clinics and GPhC-registered online pharmacies offer an alternative for people who do not meet NHS thresholds or would prefer not to wait. If you are comparing costs across private providers, the context on what weight loss injection pricing actually includes is worth reading before making a decision, headline prices do not always reflect whether a prescription, clinical review, or aftercare is included. The MHRA has warned publicly about counterfeit pens sold online, some containing insulin rather than the labelled medicine; you can verify any online pharmacy on the GPhC register before using it. Report any suspect sellers via the MHRA Yellow Card scheme.
When you are ready to explore whether either medicine is clinically suitable for you, check your eligibility with our prescribers, consultation is free, and every submission is reviewed by a GPhC-registered Independent Prescriber the same day it arrives.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.